Login
$PLSE
$46.36 -$4.08 (8.09%) Live

$PLSE 8-K SEC Filings

Filed On Filing
06 Nov 2026 8-K: Other Events

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

05 Nov 2026 8-K: Results of Operations and Financial Condition

Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System

14 Oct 2026 8-K: Other Events

Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data

07 Oct 2026 8-K: Other Events

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

15 Sep 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Mizuho Securities USA LLC (the “Agent”), as sales agent, shar...

15 Sep 2026 8-K: Other Events

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

06 Aug 2026 8-K: Entry into a Material Definitive Agreement

Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Mizuho Securities USA LLC (the “Agent”), as sales agent, shar...

06 Aug 2026 8-K: Results of Operations and Financial Condition

HAYWARD, California [Business Wire] — August 6, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business upda...

29 Jul 2026 8-K: Other Events

HAYWARD, California, July 29, 2026 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study ha...

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Pulse Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was a virtual meeting held via live audio webcast. The stockholders of the Company voted on...

10 Jun 2026 8-K: Other Events

HAYWARD, Calif.--(BUSINESS WIRE)—June 10, 2026—Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to d...

06 May 2026 8-K: Other Events

On May 5, 2026, the Board of Directors of Pulse Biosciences, Inc. (the “Company”) approved resolutions permitting TD Securities (USA) LLC, as sales agent (“TD Cowen”), to sell Company common stock to one or more Company affiliates pursua...

04 May 2026 8-K: Results of Operations and Financial Condition; Other Events

HAYWARD, California [Business Wire] – May 4, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced busin...

27 Apr 2026 8-K: Regulation FD Disclosure

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

16 Apr 2026 8-K: Regulation FD Disclosure

On April 16, 2026, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), posted an updated investor presentation on its website. The updated investor presentation (the “Investor Deck”) discloses, among other things, new detail...

09 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Employment Agreement (the “Agreement”) is made and entered into by and between Liane R. Teplitsky (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of April 8, 2026.

07 Apr 2026 8-K: Other Events

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

27 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

17 Mar 2026 8-K: Other Events

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

12 Mar 2026 8-K: Other Events

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support